ONE-WEEK USE OF RANITIDINE BISMUTH CITRATE, AMOXICILLIN AND CLARITHROMYCIN FOR THE TREATMENT OF HELICOBACTER PYLORI-RELATED DUODENAL-ULCER

Citation
Jjy. Sung et al., ONE-WEEK USE OF RANITIDINE BISMUTH CITRATE, AMOXICILLIN AND CLARITHROMYCIN FOR THE TREATMENT OF HELICOBACTER PYLORI-RELATED DUODENAL-ULCER, Alimentary pharmacology & therapeutics, 12(8), 1998, pp. 725-730
Citations number
18
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology & Pharmacy","Gastroenterology & Hepatology
ISSN journal
0269-2813
Volume
12
Issue
8
Year of publication
1998
Pages
725 - 730
Database
ISI
SICI code
0269-2813(1998)12:8<725:OUORBC>2.0.ZU;2-I
Abstract
Background: Proton pump inhibitors have been widely used in combinatio n with amoxycillin, clarithromycin or metronidazole for the treatment of Helicobacter pylori infection, Aim: To study the effects of 1-week ranitidine bismuth citrate (RBC)-based triple therapy in the treatment of H. pylori-related duodenal ulcers. Method: Patients with duodenal ulcers and H, pylori infection were prospectively randomized to receiv e either RBC with amoxycillin and clarithromycin for 1 week (RAC), or omeprazole with amoxycillin and clarithromycin for 1 week (OAC), No ad ditional ulcer healing drug was used after the 1-week medication, Pati ents were assessed for H, pylori eradication, ulcer healing and side-e ffects after receiving the therapies. Results: One hundred consecutive patients were recruited to this study, with 50 patients randomized to each treatment group, In the intention-to-treat analysis, duodenal ul cers were completely healed in 45 (90%) patients in the RAC group and 43 (89.6%) in the OAC group (P = 1.0), H. pylori eradication was confi rmed in 47 (94%) in the RAC group and 42 (87.5%) in the OAC group (P = 0.31). There was no significant difference in the severity of side-ef fects experienced by the two treatment groups, Conclusion: One-week RB C-based triple therapy is an effective treatment for H. pylori-related duodenal ulcers, The therapeutic effects are comparable to a 1-week c ourse of proton pump inhibitor-based triple therapy.